CASI Pharmaceuticals, Inc.
General ticker "CASI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $33.7M (TTM average)
CASI Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -13.9%.
Estimated limits based on current volatility of 3.3%: low 0.93$, high 0.99$
Factors to consider:
- Total employees count: 200000 as of 2022
- Top business risk factors: Pandemic risks, Cybersecurity threats, Labor/talent shortage/retention, Regulatory and compliance, Market perception risks
- Current price 44.1% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.75$, 4.74$]
- 2025-12-31 to 2026-12-31 estimated range: [1.23$, 3.37$]
Financial Metrics affecting the CASI estimates:
- Positive: with PPE of -1.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -67.21 <= 0.33
- Positive: Investing cash flow per share per price, % of 25.86 > -0.66
- Positive: Inventory ratio change, % of -19.37 <= -0.75
- Negative: Shareholder equity ratio, % of 3.45 <= 18.93
Short-term CASI quotes
Long-term CASI plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $43.11MM | $33.88MM | $28.54MM |
| Operating Expenses | $69.60MM | $58.96MM | $68.16MM |
| Operating Income | $-26.49MM | $-25.08MM | $-39.62MM |
| Non-Operating Income | $-11.79MM | $-1.21MM | $1.55MM |
| Interest Expense | $0.06MM | $0.00MM | $0.87MM |
| R&D Expense | $16.00MM | $9.86MM | $8.92MM |
| Income(Loss) | $-38.28MM | $-26.29MM | $-38.07MM |
| Taxes | $1.98MM | $0.08MM | $1.19MM |
| Profit(Loss)* | $-41.01MM | $-26.94MM | $-39.26MM |
| Stockholders Equity | $44.57MM | $24.16MM | $1.85MM |
| Inventory | $6.14MM | $15.88MM | $5.25MM |
| Assets | $96.23MM | $75.27MM | $53.67MM |
| Operating Cash Flow | $-21.09MM | $-19.97MM | $-29.22MM |
| Capital expenditure | $5.61MM | $2.24MM | $0.24MM |
| Investing Cash Flow | $31.16MM | $-9.67MM | $11.24MM |
| Financing Cash Flow | $-3.27MM | $-0.91MM | $15.43MM |
| Earnings Per Share** | $-3.01 | $-2.02 | $-2.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.